Headache medication and the COVID-19 pandemic
Antoinette MaassenVanDenBrink, Tessa de Vries, A.H. Jan Danser
Abstract
The world is currently dominated by the Corona Virus Disease 2019 (COVID-19) pandemic. Besides the obvious concerns about limitation of virus spread and providing the best possible care to infected patients, a concomitant concern has now arisen in view of a putative link between the use of certain drugs, such as Renin-Angiotensin System (RAS) inhibitors and ibuprofen, and an increased risk for COVID-19 infection. We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)PandemicPain medicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)NeurologyCoronavirus InfectionsMEDLINEAnesthesiologyVirologyPsychiatryInternal medicineInfectious disease (medical specialty)OutbreakDiseasePolitical scienceLawMigraine and Headache StudiesBlood Pressure and Hypertension StudiesLong-Term Effects of COVID-19